CYNTHIA BEDELL: Open Payments
NPI 1306976436 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,104 in 38 payments from 14 companies in 2025. Trend: 2023 $32,771 · 2024 $16,047 · 2025 $2,104
Long term medical supply or device loan: $1,097Food & beverage: $607Consulting: $400
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $1,158 |
| Daiichi Sankyo Inc. | 1 | $400 |
| Incyte Corporation | 5 | $119 |
| Stemline Therapeutics Inc. | 4 | $86 |
| Lilly USA, LLC | 3 | $75 |
| ABBVIE INC. | 3 | $75 |
| PUMA BIOTECHNOLOGY, INC. | 2 | $33 |
| AstraZeneca Pharmaceuticals LP | 1 | $31 |
| Genentech USA, Inc. | 1 | $29 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $23 |
Products named: KISQALI, Enhertu, Orserdu, MONJUVI, VERZENIO, EPKINLY, JAKAFI, NERLYNX.
Industry payments across TX — which companies pay providers there.
